COGT Key Statistics, Chart & Performance
The current stock price of COGT is 37.12 USD. In the past month the price decreased by -6.64%. In the past year, price increased by 371.07%.
COGT Latest News, Press Relases and Analysis
COGT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.31 | 406.04B | ||
| AMGN | AMGEN INC | 15.03 | 176.99B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.14 | 115.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.92 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 31.74B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 21.37B | ||
| INCY | INCYTE CORP | 15.41 | 19.42B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About COGT
Company Profile
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Company Info
COGENT BIOSCIENCES INC
275 Wyman Street, 3rd Floor
Waltham MASSACHUSETTS 02140 US
CEO: Andrew Robbins
Employees: 205
Phone: 16179455576
COGENT BIOSCIENCES INC / COGT FAQ
What does COGT do?
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
What is the stock price of COGENT BIOSCIENCES INC today?
The current stock price of COGT is 37.12 USD. The price decreased by -2.11% in the last trading session.
Does COGT stock pay dividends?
COGT does not pay a dividend.
How is the ChartMill rating for COGENT BIOSCIENCES INC?
COGT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for COGENT BIOSCIENCES INC?
COGENT BIOSCIENCES INC (COGT) has a market capitalization of 6.51B USD. This makes COGT a Mid Cap stock.
Can you provide the upcoming earnings date for COGENT BIOSCIENCES INC?
COGENT BIOSCIENCES INC (COGT) will report earnings on 2026-02-23, after the market close.
COGT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to COGT. When comparing the yearly performance of all stocks, COGT is one of the better performing stocks in the market, outperforming 99.54% of all stocks.
COGT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to COGT. While COGT seems to be doing ok healthwise, there are quite some concerns on its profitability.
COGT Financial Highlights
Over the last trailing twelve months COGT reported a non-GAAP Earnings per Share(EPS) of -1.67. The EPS increased by 32.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.42% | ||
| ROE | -71.01% | ||
| Debt/Equity | 0.15 |
COGT Forecast & Estimates
18 analysts have analysed COGT and the average price target is 50.07 USD. This implies a price increase of 34.89% is expected in the next year compared to the current price of 37.12.